Medindia

X

Reportlinker Adds Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016

Thursday, March 25, 2010 Research News J E 4
Advertisement


NEW YORK, March 24 Reportlinker.com announces that a new market research report is available in its catalogue:

Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0183456/Idiopathic-Pulmonary-Fibrosis---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Description

Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData's report on the pharmaceutical and healthcare industry - "Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. This pharma report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- Annualized global idiopathic pulmonary fibrosis revenues data from 2001 to 2009, forecast forward for 7 years to 2016.

- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.

- Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis market. Key players covered include Gilead Sciences, Inc, Actelion Ltd., Amgen Inc, InterMune, Inc. and Amarillo Biosciences

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with idiopathic pulmonary fibrosis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global idiopathic pulmonary fibrosis market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global idiopathic pulmonary fibrosis market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global idiopathic pulmonary fibrosis market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Global Idiopathic Pulmonary Fibrosis Market: Market Characterization 6

2.1 Overview 6

2.2 Idiopathic Pulmonary Fibrosis Market Size 6

2.3 Idiopathic Pulmonary Fibrosis Market Forecast and CAGR 7

2.4 Drivers and Barriers for Idiopathic Pulmonary Fibrosis Market 9

2.4.1 Drivers for Idiopathic Pulmonary Fibrosis Market 9

2.4.2 Barriers for Idiopathic Pulmonary Fibrosis Market 9

2.5 Opportunity and Unmet Need 11

2.6 Key Takeaway 12

3 Idiopathic Pulmonary Fibrosis Market: Competitive Assessment 13

3.1 Overview 13

3.2 Strategic Competitor Assessment 13

3.3 Profiles of the Major Therapeutic Class in Idiopathic Pulmonary Fibrosis 14

3.3.1 Overview 14

3.3.2 Immunosuppresants 14

3.3.3 Anti-inflammatory Drugs 15

3.3.4 Antifibrotics 15

3.4 Key Takeaway 18

4 Idiopathic Pulmonary Fibrosis Market: Pipeline Assessment 19

4.1 Overview 19

4.2 Strategic Pipeline Assessment 19

4.2.1 Technology Trends Analytic Framework 19

4.3 Idiopathic Pulmonary Fibrosis Therapeutics - Promising Drugs under Clinical Development 20

4.4 Molecule Profile for Promising Drugs for Idiopathic Pulmonary Fibrosis under Clinical Development 22

4.4.1 Letairis (ambrisentan) 22

4.4.2 Tracleer (bosentan) 23

4.4.3 Enbrel (etanercept) 24

4.4.4 Veldona (Oral interferon alfa) 25

4.5 Idiopathic Pulmonary Fibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action 26

4.6 Idiopathic Pulmonary Fibrosis Pipeline - Pipeline by Clinical Phases of Development 27

4.6.1 Idiopathic Pulmonary Fibrosis Therapeutics - Phase III Clinical Pipeline 27

4.6.2 Idiopathic Pulmonary Fibrosis Therapeutics - Phase II Clinical Pipeline 28

4.6.3 Idiopathic Pulmonary Fibrosis Therapeutics - Phase I Clinical Pipeline 28

4.6.4 Idiopathic Pulmonary Fibrosis Therapeutics - Preclinical Pipeline 29

4.6.5 Idiopathic Pulmonary Fibrosis Therapeutics - Discovery Pipeline 29

4.7 Discontinued / Suspended Drug for Idiopathic Pulmonary Fibrosis 29

4.8 Key Takeaway 30

5 Idiopathic Pulmonary Fibrosis : Implications for Future Market Competition 31

6 Idiopathic Pulmonary Fibrosis Market: Future Players in the Idiopathic Pulmonary Fibrosis Market 33

6.1 Introduction 33

6.2 Gilead Sciences, Inc., California 33

6.2.1 Overview 33

6.2.2 Respiratory Disease Portfolio 35

6.2.3 Idiopathic Pulmonary Fibrosis Product Portfolio 35

6.3 Actelion Ltd. 36

6.3.1 Overview 36

6.3.2 Respiratory Disease Portfolio 37

6.3.3 Idiopathic Pulmonary Fibrosis Product Portfolio 37

6.4 Amgen Inc. 38

6.4.1 Overview 38

6.4.2 Respiratory Disease Portfolio 39

6.4.3 Idiopathic Pulmonary Fibrosis Product Portfolio 39

6.5 InterMune, Inc. 40

6.5.1 Overview 40

6.5.2 Respiratory Disease Portfolio 42

6.6 Amarillo Biosciences 43

6.6.1 Overview 43

6.6.2 Respiratory Disease Portfolio 44

6.6.3 Idiopathic Pulmonary Fibrosis Product Portfolio 44

7 Idiopathic Pulmonary Fibrosis Market: Appendix 46

7.1 Market Definitions 46

7.2 Abbreviations 46

7.3 Research Methodology 47

7.3.1 Coverage 48

7.3.2 Secondary Research 48

7.3.3 Forecasting 49

7.3.4 Primary Research 52

7.3.5 Expert Panel validation 52

7.4 Contact Us 52

7.5 Disclaimer 52

7.6 Sources 53

List of Tables

1.1 List of Tables

Table 1: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Revenues ($m), 2001-2009 7

Table 2: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Forecast ($m), 2009-2016 8

Table 3: Major Marketed Products Comparison in the Idiopathic Pulmonary Fibrosis Market, 2010 18

Table 4: Idiopathic Pulmonary Fibrosis Therapeutics - Most Promising Drugs Under Clinical Development, 2010 20

Table 5: Idiopathic Pulmonary Fibrosis Therapeutics - Phase III Clinical Pipeline, 2010 27

Table 6: Idiopathic Pulmonary Fibrosis Therapeutics - Phase II Clinical Pipeline, 2010 28

Table 7: Idiopathic Pulmonary Fibrosis Therapeutics - Phase I Clinical Pipeline, 2010 28

Table 8: Idiopathic Pulmonary Fibrosis Therapeutics - Preclinical Pipeline, 2010 29

Table 9: Idiopathic Pulmonary Fibrosis Therapeutics - Preclinical Pipeline, 2010 29

Table 10: List of Discontinued Drugs for Idiopathic Pulmonary Fibrosis, 2010 29

Table 11: Gilead Sciences, Inc. -Respiratory Pipeline Products, 2010 35

Table 12: Actelion Ltd. -Respiratory Pipeline Products, 2010 37

Table 13: Amgen Inc. - Respiratory Disease Pipeline Products, 2010 39

Table 14: InterMune, Inc- Respiratory Disease Pipeline Products, 2010 42

Table 15: Amarillo Biosciences - Respiratory Disease Pipeline Products, 2010 44

List of Figures

1.2 List of Figures

Figure 1: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Revenues ($m), 2001-2009 7

Figure 2: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Forecast ($m), 2009-2016 8

Figure 3: Opportunity and Unmet Need in the Idiopathic Pulmonary Fibrosis Market, 2010 12

Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Idiopathic Pulmonary Fibrosis, 2010 13

Figure 5: Technology Trends Analytic Framework of the Idiopathic Pulmonary Fibrosis Pipeline, 2010 19

Figure 6: Technology Trends Analytic Framework of the Idiopathic Pulmonary Fibrosis Pipeline - Description, 2010 20

Figure 7: Idiopathic Pulmonary Fibrosis Therapeutics - Clinical Pipeline by Mechanism of Action, 2010 26

Figure 8: Idiopathic Pulmonary Fibrosis Pipeline by Phase of Clinical Development, 2010 27

Figure 9: Implications for Future Market Competition in the Idiopathic Pulmonary Fibrosis Market, 2010 31

Figure 10: Idiopathic Pulmonary Fibrosis Therapeutics Market - Clinical Pipeline by Company, 2010 33

Figure 11: GlobalData Methodology, 2010 48

Figure 11: GlobalData Market Forecasting Model 51

To order this report:

Medical Devices Industry: Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Medical Equipment Monthly Deals ...
S
Reportlinker Adds Biotechnology (Pharmaceuticals) ...